Dendreon Corp fka DNDNQ

[mouton29]

<<Docetaxel's p-value in the 772 patients clinical trial with way more events than IMPACT merely demonstrated a p-value of 0.01, and an HR of 0.76.

With that type of treatment effect, docetaxel may only demonstrate a p-value of 0.2 at 94 deaths (the events in trial 9901).

So another way to look at this is FDA in essence approved a drug with 20-fold (0.2 vs 0.01) higher chance of being a placebo with much more toxicity, had it been subjected to the same clinical trial condition of 9901.>>

I don't follow this. Are you saying that evidence from a large clinical trial should be rejected because, had a smaller clinical been run and had the results been proportionately the same, the p-value would have been higher? But the larger trial was run, and in this case, a placebo would have produced the results in question in 1% of the cases. What's the relevance of the fact that a smaller trial could have been run?